1 unchanged sentence
Evaluation of Disclosure Controls and Procedures
−Removed: Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive and principal financial officers, respectively, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended, as of the end of the period covered by this Annual Report on Form 10-K.
−Removed: Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of December 31, 2024, our disclosure controls and procedures were effective (a) to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (b) to include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
+Added: Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, who serve as our principal executive officer and principal financial officer, respectively, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this Annual Report on Form 10-K.
+Added: Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2025, our disclosure controls and procedures were effective to provide a reasonable assurance (a) that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (“SEC”), and (b) that such information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act.
−Removed: Under the supervision and with the participation of senior management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our internal control over financial reporting based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework).
−Removed: Based on the evaluation under that framework and applicable SEC rules, our management concluded that our internal control over financial reporting was effective as of December 31, 2024.
+Added: Under the supervision and with the participation of senior management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our internal control over financial reporting based on the framework and criteria set forth in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework).
+Added: Based on the evaluation under that framework and applicable SEC rules, our management concluded that our internal control over financial reporting was effective at a reasonable assurance level as of December 31, 2025.
The Company’s independent registered public accounting firm, Ernst & Young LLP, has issued an attestation report on the effectiveness of our internal control over financial reporting as of December 31, 2025, which is included in this Item 9A under the caption "Report of Independent Registered Public Accounting Firm."
1 unchanged sentence
There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
−Removed: Inherent Limitations of Internal Controls
+Added: Inherent Limitations of Disclosure Controls and Procedures and Internal Controls Over Financial Reporting
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all errors and all fraud.
41 unchanged sentences
We will post any amendments to the Code of Conduct on our website.
−Removed: In accordance with the requirements of the SEC and Nasdaq, we will also post waivers applicable to any of our officers or directors from provisions of the Code of Conduct on our website.
+Added: In accordance with the requirements of the SEC and Nasdaq Stock Market LLC, we will also post waivers applicable to any of our officers or directors from provisions of the Code of Conduct on our website.
Executive Compensation.
4 unchanged sentences
The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2026 Annual Meeting of Stockholders.
−Removed: Principal Accounting Fees and Services.
+Added: Principal Accountant Fees and Services.
The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2026 Annual Meeting of Stockholders.
−Removed: Exhibits, Financial Statement Schedules.
+Added: Exhibits and Financial Statement Schedules.
(a) The following documents are filed as part of this Annual Report on Form 10-K:
−Removed: (1) Financial Statements.
−Removed: See Item 8 “Consolidated Financial Statements and Supplementary Data” elsewhere in this Annual Report on Form 10-K.
+Added: (1) Consolidated Financial Statements.
+Added: See Item 8 “Financial Statements and Supplementary Data” elsewhere in this Annual Report on Form 10-K.
(2) Financial Statement Schedules.
53 unchanged sentences
Christopher Marmo, as Contributors’ Representative, and acknowledged by the parties listed as Contributors on the signature pages thereto.
+Added: 001-38381 10.17
Employment Agreement, dated as of May 6, 2018, by and between David Moatazedi and the Registrant.
6 unchanged sentences
10-Q 001-38381 10.4 8/2/22
−Removed: Employment Agreement, dated September 5, 2022, by and between Sandra Beaver and the Registrant.
+Added: 10.21+ Employment Agreement, dated September 8 , 202 5 , by and between Tatjan a Mitchell and the Registrant.
10-Q 001-38381 10.1 11/5/25
4 unchanged sentences
10-Q 001-38381 10.3 5/12/21
−Removed: Share Issuance Agreement, dated February 18, 2021, by and between Evolus Inc.
−Removed: and Medytox, Inc.
−Removed: 10-Q 001-38381 10.4 5/12/21
Confidential Settlement and Release Agreement, dated March 23, 2021, by and between Evolus, Inc.
4 unchanged sentences
10-Q 001-38381 10.7 5/12/21
−Removed: 10.27‡ Loan Agreement, dated as of December 14, 2021, by and among Evolus, Inc.
−Removed: (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).
−Removed: 8-K 001-38381 10.1 12/14/21
−Removed: 10.28 First Amendment to Loan Agreement, dated April 5, 2022, by and among Evolus, Inc.
−Removed: (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).
−Removed: 10-Q 001-38381 10.2 8/2/22
−Removed: 10.29 Second Amendment to Loan Agreement, dated as of December 5, 2022, by and among Evolus, Inc.
+Added: Amended and Restated Loan Agreement, dated as of May 5, 2025, by and among Evolus, Inc.
(as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).
−Removed: 8-K 001-38381 10.1 12/8/22
Fourth Amendment to Supply Agreement, dated December 12, 2022, by and between Evolus, Inc.
7 unchanged sentences
10-Q 001-38381 10.2 8/2/23
−Removed: 10.33 Third Amendment to Loan Agreement, dated as of May 9, 2023, by and among Evolus, Inc.
−Removed: (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).
−Removed: 10-Q 001-38381 10.3 8/2/23
−Removed: Employment Agreement, dated August 21, 2023, by and between Tomoko Yamagishi-Dressler and the Registrant.
−Removed: 10-Q 001-38381 10.2 11/7/23
License, Supply, and Distribution Agreement (Europe), dated as of December 20, 2024, by and between Evolus Pharma B.V.
6 unchanged sentences
001-38381 10.1
−Removed: S econd Amendment to Lease, dated as of October 16, 2024 , by and between t h e Registrant and 520 Newport Center Drive LLC
+Added: Seventh Amendment to Supply Agreement, dated as of September 9, 2025, by and between Daewoong Pharmaceutical Co.
+Added: and Evolus, Inc.
+Added: Second Amendment to Lease, dated as of October 16, 2024, by and between the Registrant and 520 Newport Center Drive LLC.
2024 Employee Stock Purchase Plan.
20 unchanged sentences
Form 10-K Summary.
+Added: None, we have elected not to provide summary information.
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 3, 2026.
4 unchanged sentences
The undersigned directors and officers of Evolus, Inc.
−Removed: constitute and appoint David Moatazedi and Sandra Beaver, and each of them, as their true and lawful attorneys and agents with power of substitution, to do any and all acts and things in our name and behalf in our capacities as directors and officers and to execute any and all instruments for us and in our names in the capacities indicated below, which said attorneys and agents may deem necessary or advisable to enable said corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with this Annual Report on Form 10-K, including specifically but without limitation, power and authority to sign for us or any of us in our names in the capacities indicated below, any and all amendments hereto;
+Added: constitute and appoint David Moatazedi and Tatjana Mitchell, and each of them, as their true and lawful attorneys and agents with power of substitution, to do any and all acts and things in our name and behalf in our capacities as directors and officers and to execute any and all instruments for us and in our names in the capacities indicated below, which said attorneys and agents may deem necessary or advisable to enable said corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with this Annual Report on Form 10-K, including specifically but without limitation, power and authority to sign for us or any of us in our names in the capacities indicated below, any and all amendments hereto;
and we do hereby ratify and confirm all that said attorneys and agents shall do or cause to be done by virtue hereof.
6 unchanged sentences
David Moatazedi
−Removed: /s/ Sandra Beaver Chief Financial Officer
+Added: /s/ Tatjana Mitchell Chief Financial Officer
(Principal Financial Officer) March 3, 2026
−Removed: Sandra Beaver
+Added: Tatjana Mitchell
/s/ Vikram Malik Chairman of the Board of Directors March 3, 2026
−Removed: /s/ Simone Blank Director March 4, 2025
/s/ David Gill Director March 3, 2026
3 unchanged sentences
Brady Stewart
−Removed: Signature Title Date
/s/ Albert G.
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.